Similarly, Preclinical data demonstrate that pharmacological inhibition of METTL1 using METTL1-WDR4-IN-1, in combination with the PKM2 inhibitor shikonin, significantly impairs tumor growth in murine CRC models, with greater efficacy observed than with either agent alone [77]​. The gene discussed is PKM; the disease is neoplasm.